XML 47 R39.htm IDEA: XBRL DOCUMENT v3.23.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Information [Abstract]

Schedule of Segment Information

we operate in the following two reportable business segments:

		During the Three-Month Period Ended September 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	5,360,063			$	36,437			$	—			$	5,396,500
Costs of goods sold			4,095,164				34,455				—				4,129,619
Gross margin			1,264,899				1,982				—				1,266,881
Product development expense			—				1,082,346				36,143				1,118,489
Sales and marketing expenses			641,682				175,804				—				817,486
Administrative expenses			—				—				514,952				514,952
Operating expenses			641,682				1,258,150				551,095				2,450,927
NET OPERATING INCOME (LOSS)		$	623,217			$	(1,256,168	)		$	(551,095	)		$	(1,184,046	)

		During the Three-Month Period Ended September 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	4,751,049			$	44,976			$	—			$	4,796,025
Costs of goods sold			2,898,897				45,441				5,636				2,949,974
Gross margin			1,852,152				(465	)			(5,636	)			1,846,051
Product development expenses			6,421				1,246,243				17,097				1,269,761
Sales and marketing expenses			369,439				357,299				—				726,738
Administrative expenses			—				—				466,342				466,342
Operating expenses			375,860				1,603,542				483,439				2,462,841
NET OPERATING INCOME (LOSS)		$	1,476,292			$	(1,604,007	)		$	(489,075	)		$	(616,790	)

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2023		$	24,119,683			$	18,132,922			$	2,292,417			$	44,545,022
Total Assets as of September 30, 2022		$	18,678,408			$	18,634,760			$	9,088,393			$	46,401,561
Depreciation and amortization expense during the three-month period ended September 30, 2023		$	355,673			$	328,381			$	25,044			$	709,098
Depreciation and amortization expense during the three-month period ended September 30, 2022		$	302,235			$	316,317			$	15,688			$	634,240
Capital Expenditures during the three-month period ended September 30, 2023		$	341,386			$	79,129			$	—			$	420,515
Capital Expenditures during the three-month period ended September 30, 2022		$	665,825			$	21,032			$	47,452			$	734,309

		During the Nine-Month Period Ended September 30, 2023
		Scours				Mastitis				Other				Total
Product sales		$	12,253,555			$	122,153			$	—			$	12,375,708
Costs of goods sold			9,652,292				111,872				—				9,764,164
Gross margin			2,601,263				10,281				—				2,611,544
Product development expenses			2,543				3,220,075				105,779				3,328,397
Sales and marketing expenses			1,890,404				526,297				—				2,416,701
Administrative expenses			—				—				1,611,026				1,611,026
Operating expenses			1,892,947				3,746,372				1,716,805				7,356,124
NET OPERATING INCOME (LOSS)		$	708,316			$	(3,736,091	)		$	(1,716,805	)		$	(4,744,580	)

		During the Nine-Month Period Ended September 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	14,537,390			$	118,237			$	1,455			$	14,657,082
Costs of goods sold			7,870,420				104,092				25,967				8,000,479
Gross margin			6,666,970				14,145				(24,512	)			6,656,603
Product development expenses			23,025				3,331,311				90,128				3,444,464
Sales and marketing expenses			1,127,676				1,069,801				—				2,197,477
Administrative expenses			—				—				1,679,851				1,679,851
Operating expenses			1,150,701				4,401,112				1,769,979				7,321,792
NET OPERATING INCOME (LOSS)		$	5,516,269			$	(4,386,967	)		$	(1,794,491	)		$	(665,189	)

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2023		$	24,119,683			$	18,132,922			$	2,292,417			$	44,545,022
Total Assets as of September 30, 2022		$	18,678,408			$	18,634,760			$	9,088,393			$	46,401,561
Depreciation and amortization expense during the nine-month period ended September 30, 2023		$	1,020,909			$	969,666			$	64,066			$	2,054,641
Depreciation and amortization expense during the nine-month period ended September 30, 2022		$	894,856			$	947,067			$	47,144			$	1,889,067
Capital Expenditures during the nine-month period ended September 30, 2023		$	1,038,033			$	773,136			$	—			$	1,811,169
Capital Expenditures during the nine-month period ended September 30, 2022		$	2,050,107			$	387,536			$	47,452			$	2,485,095

		During the Year Ended December 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	18,411,949			$	154,558			$	1,455			$	18,567,962
Costs of goods sold			10,754,189				136,347				28,647				10,919,183
Gross margin			7,657,760				18,211				(27,192	)			7,648,779
Product development expenses			66,346				4,317,921				109,605				4,493,872
Sales and marketing expenses			1,871,926				1,318,107				—				3,190,033
Administrative expenses			—				—				2,263,817				2,263,817
Operating expenses			1,938,272				5,636,028				2,373,422				9,947,722
NET OPERATING INCOME (LOSS)		$	5,719,488			$	(5,617,817	)		$	(2,400,614	)		$	(2,298,943	)

		During the Year Ended December 31, 2021
		Scours				Mastitis				Other				Total
Product sales		$	18,933,092			$	143,280			$	166,597			$	19,242,969
Costs of goods sold			10,411,936				99,957				75,147				10,587,040
Gross margin			8,521,156				43,323				91,450				8,655,929
Product development expenses			25,374				3,887,781				255,363				4,168,518
Sales and marketing expenses			1,942,391				561,535				—				2,503,926
Administrative expenses			—				—				1,726,100				1,726,100
Operating expenses			1,967,765				4,449,316				1,981,463				8,398,544
NET OPERATING INCOME (LOSS)		$	6,553,391			$	(4,405,993	)		$	(1,890,013	)		$	257,385

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2022		$	20,539,523			$	18,315,492			$	6,005,634			$	44,860,649
Total Assets as of December 31, 2021		$	14,860,769			$	19,122,265			$	10,482,654			$	44,465,688
Depreciation and amortization expense during the year ended December 31, 2022		$	1,169,011			$	1,263,318			$	62,912			$	2,495,241
Depreciation and amortization expense during the year ended December 31, 2021		$	1,032,735			$	1,374,171			$	62,075			$	2,468,981
Capital Expenditures during the year ended December 31, 2022		$	3,513,336			$	414,486			$	47,452			$	3,975,274
Capital Expenditures during the year ended December 31, 2021		$	1,632,855			$	975,794			$	—			$	2,608,649

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration